Issue Highlights

The management of patients with eosinophilic esophagitis remains challenging.1,2 In routine practice, treatment includes either swallowed steroids or dietary exclusion therapy as a first line, but many patients need chronic use of these strategies with high rates of symptom recurrence upon steroid cessation or re-introduction of culprit foods. In this issue of Clinical Gastroenterology and Hepatology, Dellon and colleagues3 report on the observational phase of a randomized double-blind trial comparing oral viscous budesonide to multi-dose inhaled fluticasone for eosinophilic esophagitis.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Issue Highlights Source Type: research